Authorization

Very Strong Increase of Sales During the Third Quarter

STOCKHOLM, Nov. 5, 2019 /PRNewswire/ -- Q3

Net sales reached SEK 19.5 (13.2) million.



Result after tax came in at SEK -7.7 (-9.6) million.



Earnings per share, basic and diluted, were SEK
-0.05 (-0.11).



Cash and cash equivalents were SEK 30.7 (9.5) million.

Significant events in Q3

Enzymatica launched ColdZymeA® Strawberry and broadened use to include soothe sore throat and alleviate common cold symptoms.



Sales surged on the Swedish market and ColdZyme continued to capture market share in terms of both value and volume. Sales on the Danish and Spanish markets also showed strong growth.



Preliminary results from Enzymatica's placebo-controlled, randomized study of ColdZyme did not meet the primary end-point of improved quality of life among cold sufferers.

First nine months

Net sales reached SEK 39.2 (33.6) million.



Result after tax came in at SEK -35.6 (-35.2) million.



Earnings per share, basic and diluted, were SEK -0.25 (-0.39).



Key figures




























(SEK THOUSAND)
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2019    »
ПнВтСрЧтПтСбВс
 123
45678910
11121314151617
18192021222324
252627282930